Riedl, Elisabeth http://orcid.org/0009-0008-2765-5417
Pinter, Andreas
Zaheri, Shirin
Costanzo, Antonio
Brnabic, Alan
Konicek, Bruce
McKenzie, Robert
Lampropoulou, Anastasia
Rayes, Mohamed El
Haustrup, Natalie
Schuster, Christopher
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 22 February 2024
Accepted: 25 March 2024
First Online: 22 April 2024
Declarations
:
: Elisabeth Riedl is a former employee, has pending patents with Eli Lilly and Company and has also been a speaker and/or consultant for Eli Lilly and Company, Pelpharma, Novartis, Almirall. Andreas Pinter has served as an investigator, speaker, and/or consultant for AbbVie, Almirall-Hermal, Amgen, Biogen Idec, BioNTech, Boehringer Ingelheim, Celgene, GSK, Eli Lilly and Company, Galderma, Hexal, Janssen, LEO Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough und UCB Pharma. Shirin Zaheri has served as advisory board member or has received fees and speaker’s honoraria for AbbVie, Biogen, Eli Lilly and Company, Leo Pharma, L’Oréal and Novartis. Antonio Costanzo served as advisory board member and consultant, and/or has received fees and/or speaker’s honoraria and/or has participated to clinical trials for Abbvie, Almirall, Amgen, Eli Lilly and Company, Janssen, Novartis, Sanofi and UCB and is president of European Dermatology Forum and has received payment to participate on the advisory boards for IQVIA. Alan Brnabic, Bruce Konicek, Robert McKenzie, Anastasia Lampropoulou, Mohamed El Rayes, Natalie Haustrup, Christopher Schuster are all employees and minor shareholders of Eli Lilly and Company.
: The protocol, amendments, and consent documentation were approved by local institutional review boards (IRB). The study was registered at the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP24207) and was conducted according to International Conference on Harmonization, Good Clinical Practice guidelines, and the Declaration of Helsinki. All patients were required to give informed consent for participation in the study. We confirm that the necessary central or local IRB and/or ethics committee approvals have been obtained for this multi-site, international study by United BioSource LLC (UBC). Approvals can be provided on request.